Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$93.47−4.16 (-4.26%)
Close on Nov 20, 2026Market cap $8.24BP/E –Yield –
Spyre Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Spyre Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$201.34M. For fiscal 2025 it was -$209.56M. The highest annual figure on record is -$8.90M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$209.56M | – |
| FY2024 | Dec 31, 2024 | -$208.57M | – |
| FY2023 | Dec 31, 2023 | -$242.30M | – |
| FY2022 | Dec 31, 2022 | -$84.78M | – |
| FY2021 | Dec 31, 2021 | -$65.65M | – |
| FY2020 | Dec 31, 2020 | -$81.48M | – |
| FY2019 | Dec 31, 2019 | -$80.33M | – |
| FY2018 | Dec 31, 2018 | -$45.46M | – |
| FY2017 | Dec 31, 2017 | -$27.68M | – |
| FY2016 | Dec 31, 2016 | -$21.91M | – |
| FY2015 | Dec 31, 2015 | -$11.32M | – |
| FY2014 | Dec 31, 2014 | -$8.90M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$41.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$45.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$57.17M | – |
| Q3 FY2025 | Sep 30, 2025 | -$56.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.94M | – |
| Q1 FY2025 | Mar 31, 2025 | -$53.57M | – |
| Q4 FY2024 | Dec 31, 2024 | -$61.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$44.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$47.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$45.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$159.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.81M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.76M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$22.78M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.12M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.02M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.91M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.15M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.62M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.25M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.63M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.00M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.72M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.33M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.54M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.30M | – |
See a number that looks wrong?